Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on mast cell biology and antibody-based therapeutics for allergic, inflammatory, autoimmune and other mast cell-mediated diseases. Company updates center on barzolvolimab, a humanized monoclonal antibody being studied across chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, as well as pipeline work that includes CDX-622 in asthma.
Recurring news themes include clinical data presentations at allergy and dermatology meetings, financial results, corporate updates and capital actions. Celldex also reports financing activity tied to its common stock and development priorities for its antibody-based immunology pipeline.
Celldex Therapeutics (NASDAQ:CLDX) announced the appointment of Cheryl L. Cohen and Dr. Garry Neil to its Board of Directors on June 16, 2022. Their extensive backgrounds in the pharmaceutical and biotechnology sectors are expected to support the company's clinical and corporate objectives. Cohen, previously Chief Commercial Officer of Medivation, brings commercialization experience, while Dr. Neil has held pivotal roles at various biotech firms and offers deep scientific expertise. This leadership addition aims to bolster Celldex's strategy as it advances its therapeutic pipeline.
Celldex Therapeutics (NASDAQ:CLDX) announced that its senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 a.m. ET in New York City. This event will provide insights into the company's advancements in monoclonal and bispecific antibodies aimed at treating severe diseases.
A webcast of the presentation will be accessible on the Investors & Media section of the Celldex website, with a replay available for 30 days afterward.
Celldex Therapeutics (NASDAQ:CLDX) announced the acceptance of an abstract detailing the Phase 1b study of barzolvolimab (CDX-0159) for patients with antihistamine refractory chronic spontaneous urticaria (CSU). This late-breaking electronic poster presentation will occur at the EAACI Annual Congress 2022 from July 1-3, 2022. The study aims to evaluate the safety and efficacy of multiple ascending doses in 40 patients who continue to experience symptoms despite antihistamine treatment. Results will include findings from various dosage cohorts.
Celldex Therapeutics (NASDAQ:CLDX) reported its Q1 2022 financial results, highlighting a net loss of $23.1 million ($0.49 per share), up from a loss of $16.5 million in Q1 2021. Total revenue decreased to $0.2 million from $0.7 million due to reduced services under agreements with Rockefeller University and Gilead Sciences. R&D expenses rose to $17.1 million, and G&A expenses increased to $6.9 million. The company remains on track with its clinical programs, including the Phase 1b study of barzolvolimab for chronic spontaneous urticaria, with a Phase 2 initiation expected this quarter.
Celldex Therapeutics (NASDAQ: CLDX) reported its 2021 financial results, highlighting a 95% complete response rate in its Phase 1b study for chronic inducible urticaria with CDX-0159. The firm holds $408.3 million in cash, sufficient to fund operations through 2025. Phase 2 studies for chronic spontaneous urticaria and eosinophilic esophagitis are set to begin in Q2 2022 and Q4 2022, respectively. However, total revenues dropped to $0.3 million in Q4 2021 compared to $3.8 million in Q4 2020, and the net loss for the year was $70.5 million.
Celldex Therapeutics (NASDAQ:CLDX) will host a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its Q4 and full year 2021 financial results and corporate updates. Interested parties can access the live or recorded webcast on the company's website. Celldex focuses on developing monoclonal and bispecific antibodies targeting serious diseases with inadequate treatments. Their pipeline aims to enhance patient outcomes in cancer and inflammatory diseases.
Celldex Therapeutics (NASDAQ:CLDX) announced its participation in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:00 p.m. ET. Senior management will represent the company during this event. Interested parties can access a webcast of the presentation via the company's 'Events & Presentations' page, with a replay available for 30 days afterward. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating severe diseases, including various cancers and inflammatory diseases.
Celldex Therapeutics (NASDAQ:CLDX) announced the first patient has been dosed in a Phase 1 study of CDX-0159 for prurigo nodularis (PN), a debilitating skin disease. This monoclonal antibody targets the KIT receptor to aid in reducing chronic itch linked to PN. The study will enroll about 40 patients divided into four groups, assessing safety and clinical effects over 8 weeks. The Chief Medical Officer highlighted the milestone's potential impact on patients suffering from PN, as there are currently no approved treatments.
Celldex Therapeutics (NASDAQ:CLDX) announced promising preclinical results for CDX-585, a bispecific antibody targeting ILT4 and PD-1 pathways, at the SITC 2021 meeting. The data indicate that CDX-585 successfully merges blockade of these checkpoints, enhancing T cell activation and demonstrating anti-tumor effects in humanized melanoma models. This marks the first advancement from a collaboration with Biosion, Inc. and supports the initiation of manufacturing and IND-enabling studies, with significant implications for immune response in cancer therapy.
Celldex Therapeutics (NASDAQ:CLDX) will participate in several virtual investor conferences in November 2021. Notable events include the Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on November 16 at 10:20 a.m. ET, the Jefferies London Healthcare Conference available on-demand starting November 18 at 3:00 a.m. ET, and the Evercore ISI 4th Annual HealthCONx Conference on November 30 at 8:25 a.m. ET. Webcasts of these presentations will be accessible on the Celldex website for 30 days post-event.